Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous corneal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate

Drug Profile

Autologous corneal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate

Alternative Names: GPLSCD-01; Holoclar; Limbal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate; Living tissue equivalent - Chiesi/Holostem Terapie Avanzate

Latest Information Update: 14 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi; Holostem Terapie Avanzate
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Limbal stem cell deficiency
  • New Molecular Entity No

Highest Development Phases

  • Marketed Limbal stem cell deficiency

Most Recent Events

  • 12 Jun 2018 Launched for Limbal stem cell deficiency in Ireland and United Kingdom (Ophthalmic)
  • 12 Jun 2018 Autologous corneal epithelial stem cell therapy - Chiesi/Holostem Terapie Avanzate receives Orphan Drug status for Limbal stem cell deficiency in USA
  • 05 Sep 2017 Autologous corneal epithelial stem cell therapy is still registered for Limbal stem cell deficiency in European Union, Norway, Iceland and Liechtenstein (Opthalmic) (Chiesi pipeline, September 2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top